Regeneron Pharmaceuticals (NasdaqGS:REGN) was removed from multiple key indices, a development that may influence its investment appeal and stock liquidity. Over the last month, the company's shares ...

Notably, the first FDA-approved biologic was dupilumab (Dupixent; Regeneron, Sanofi), and this approval took place less than 1 year ago in September 2024. Khavandi: Inhaled therapy — viewed as a ...